Trial Profile
A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary) ; Enzalutamide (Primary) ; Finasteride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 28 Dec 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2023 Planned End Date changed from 1 Sep 2024 to 1 Oct 2023.
- 13 Jul 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Oct 2023.